Please try another search
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Vikas Sinha | 58 | 2016 | Independent Non-Executive Director |
Anders Ullman | 65 | 2015 | Independent Non-Executive Director |
David R. Ebsworth | 67 | 2014 | Independent Non-Executive Chairman |
Kenneth Thomas Cunningham | 68 | 2015 | Independent Non-Executive Director |
David S. Zaccardelli | 56 | 2020 | President, CEO & Executive Director |
Mahendra Gopaldas Shah | 79 | 2016 | Independent Non-Executive Director |
Martin William Edwards | 68 | 2019 | Independent Non-Executive Director |
James Brady | 61 | 2022 | Independent Non-Executive Director |
Lisa Deschamps | 52 | 2021 | Independent Non-Executive Director |
Christina M. Ackermann | 59 | 2023 | Non-Executive Director |
Michael Austwick | 55 | 2024 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review